<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949244</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-2686</org_study_id>
    <nct_id>NCT03949244</nct_id>
  </id_info>
  <brief_title>Nailfold Capillary Blood Flow With Latanoprost Bunod</brief_title>
  <official_title>Effect of Nailfold Application of Latanoprostene Bunod on Nailfold Capillary Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the relationship of small blood vessels&#xD;
      irregularities observed with an imaging system called video nailfold capillaroscopy in people&#xD;
      with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a&#xD;
      magnifying lens used for studying the movement of blood in small blood vessels. It is simple,&#xD;
      safe and does not penetrate the skin. The skin fold that is at the tip of the finger is&#xD;
      called the &quot;nailfold&quot;. NFC has been used to assess blood vessel narrowing in patients with&#xD;
      glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the study team investigates the effect of topically-applied latanoprostene&#xD;
      bunod (LTB) on the blood flow at the nailfold of the 4th finger in patients with primary open&#xD;
      angle glaucoma. LTB is a new anti-glaucoma eye drop which received FDA clearance in early&#xD;
      November 2017. It has two components: the prostaglandin analog (PGA) which decreases&#xD;
      intraocular pressure (IOP) by enhancing the drainage of the aqueous (the fluid in the front&#xD;
      part of the eye) from the eye, and the nitric oxide (NO) moiety which naturally dilates&#xD;
      arteries in the body. The capillaries at the nailfold are comparable to those of the optic&#xD;
      nerve head, which makes them a reasonable surrogate for evaluation of the effect of LTB on&#xD;
      the blood flow. Therefore, this study may provide indirect evidence for the beneficial effect&#xD;
      of LTB on blood flow to optic nerve which can potentially save the optic nerve from&#xD;
      glaucomatous damage. Primary open angle glaucoma is a progressive condition and is the most&#xD;
      common cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is a&#xD;
      subset of the glaucomas defined by an open, normal appearing anterior chamber angle and&#xD;
      raised intraocular pressure (IOP), with no other underlying disease.&#xD;
&#xD;
      In addition to LTB, the study team will use latanoprost (L), an-FDA approved PGA&#xD;
      anti-glaucoma eye drop and normal saline (NS: the physiologic solution composed of 0.9% salt&#xD;
      and water), as controls to make sure the effects of LPB on nail fold capillary blood flow is&#xD;
      not due to its PGA (as L is) or due to the placebo effect (as NS is).&#xD;
&#xD;
      This study may also serve as background information for the development of new anti-glaucoma&#xD;
      medications which can be injected into the eye to facilitate blood flow to the optic nerve.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Patients will have baseline NFC blood flow measurements after application of cedar oil. Then the study team will use NF application of either normal saline, latanoprost 0.005% or LTB 0.024% in random sequence. The patient and imager will know which study article is applied. NFC blood flow will be remeasured after 15 minutes. Preliminary data on controls suggests that 15 minutes is sufficient time to see a change in blood flow. NF article application will occur on a specially designed well applied to the 4th digit of the non-dominant hand. Two masked observers will evaluate NFC blood flow.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NFC Blood Flow at Baseline and 15 Minutes</measure>
    <time_frame>baseline and 15 minutes</time_frame>
    <description>NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Latanoprost 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% drops to the nailfold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost bunod 0.024%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost bunod 0.024% drops to the nailfold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0.9% to the nailfold.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005%</intervention_name>
    <description>Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.</description>
    <arm_group_label>Latanoprost 0.005%</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost bunod 0.024%</intervention_name>
    <description>Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.</description>
    <arm_group_label>Latanoprost bunod 0.024%</arm_group_label>
    <other_name>Vyzulta</other_name>
    <other_name>LTB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline 0.9%</intervention_name>
    <description>Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.</description>
    <arm_group_label>Normal saline 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nailfold capillaroscopy</intervention_name>
    <description>An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.</description>
    <arm_group_label>Latanoprost 0.005%</arm_group_label>
    <arm_group_label>Latanoprost bunod 0.024%</arm_group_label>
    <arm_group_label>Normal saline 0.9%</arm_group_label>
    <other_name>NFC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 years old to 80 years old&#xD;
&#xD;
          -  All participants will have open angles and no signs of secondary glaucoma such as&#xD;
             exfoliation syndrome&#xD;
&#xD;
          -  Untreated intraocular pressure (IOP) may be ≤ 21mmHg or ≥ 21mmHg in both eyes&#xD;
&#xD;
          -  The cup-to-disc ratio (CDR) ≥ 0.6 in both eyes and CDR asymmetry ≤ 0.2.&#xD;
&#xD;
          -  POAG patients will have reliable Humphrey Visual Field (HVF) loss consistent with&#xD;
             optic nerve damage&#xD;
&#xD;
          -  POAG patients can have any stage of POAG and be on any form of treatment for their&#xD;
             disease.&#xD;
&#xD;
          -  Willingness to sign informed consent and comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of non-POAG forms of glaucoma&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ritch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <results_first_submitted>July 29, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>James Tsai</investigator_full_name>
    <investigator_title>Professor and System Chair of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Nailfold capillary imaging</keyword>
  <keyword>Latanoprost bunod</keyword>
  <keyword>Latanoprost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results of the study will be shared as publications in peer-reviewed journals and at scientific meetings. All data to be shared will be de-identified. Study subjects may request to learn the results of the study, which will be provided orally by the study staff, or they will be referred to any publications.</ipd_description>
    <ipd_time_frame>Results will be shared upon completion of the study.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03949244/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred at New York Eye and Ear Infirmary of Mount Sinai</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Latanoprost 0.005%</title>
          <description>Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired.&#xD;
Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.</description>
        </group>
        <group group_id="P2">
          <title>Latanoprost Bunod 0.024%</title>
          <description>Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
        <group group_id="P3">
          <title>Normal Saline 0.9%</title>
          <description>Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Latanoprost 0.005%</title>
          <description>Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired.&#xD;
Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.</description>
        </group>
        <group group_id="B2">
          <title>Latanoprost Bunod 0.024%</title>
          <description>Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
        <group group_id="B3">
          <title>Normal Saline 0.9%</title>
          <description>Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.08" spread="5.95"/>
                    <measurement group_id="B2" value="66.95" spread="8.86"/>
                    <measurement group_id="B3" value="66.5" spread="8.50"/>
                    <measurement group_id="B4" value="66.84" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NFC Blood Flow at Baseline and 15 Minutes</title>
        <description>NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.</description>
        <time_frame>baseline and 15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost 0.005%</title>
            <description>Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired.&#xD;
Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.</description>
          </group>
          <group group_id="O2">
            <title>Latanoprost Bunod 0.024%</title>
            <description>Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
          </group>
          <group group_id="O3">
            <title>Normal Saline 0.9%</title>
            <description>Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>NFC Blood Flow at Baseline and 15 Minutes</title>
          <description>NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.</description>
          <units>pL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.52" spread="37.76"/>
                    <measurement group_id="O2" value="83.94" spread="78.31"/>
                    <measurement group_id="O3" value="93.01" spread="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.50" spread="42.81"/>
                    <measurement group_id="O2" value="75.57" spread="44.68"/>
                    <measurement group_id="O3" value="69.70" spread="41.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Latanoprost 0.005%</title>
          <description>Latanoprost 0.005% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired.&#xD;
Nailfold capillaroscopy: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.</description>
        </group>
        <group group_id="E2">
          <title>Latanoprost Bunod 0.024%</title>
          <description>Latanoprost bunod 0.024% drops applied to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
        <group group_id="E3">
          <title>Normal Saline 0.9%</title>
          <description>Normal saline 0.9% to the nailfold and images of the blood flow in the nailfold capillaries acquired via nailfold capillaroscopy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harriet Lloyd</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-979-4672</phone>
      <email>hlloyd@nyee.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

